ORYZON to Participate in Upcoming Events in February and March
MWN-AI** Summary
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical leader in epigenetics, has announced its participation in several key industry events scheduled for February and March 2026. These events include the Bio-Neuroscience 2026, taking place from February 24-27 in Amsterdam, and the SmallCap Event on March 17 in Paris. Additionally, Oryzon will participate in the BIO-Europe Spring 2026 from March 23-25 in Lisbon, and the LSX World Congress Europe on March 25-26, where Oryzon leaders will engage in a panel discussion at 14:00 GMT.
Founded in 2000 and headquartered in Barcelona, Oryzon focuses on personalized medicine for central nervous system (CNS) disorders and oncology. The company boasts a strong clinical portfolio featuring innovative LSD1 inhibitors, including vafidemstat, its lead CNS program, which is prepared for Phase III trials. The company's oncology program for iadademstat has shown promising results in Phase I and II studies, particularly for acute myeloid leukemia, achieving a remarkable 100% overall response rate presented at ASH 2025.
Beyond its primary programs, Oryzon is exploring a diverse epigenetics pipeline targeting mechanisms like HDAC6, with a promising clinical candidate, ORY-4001, aimed at treating Charcot–Marie–Tooth disease (CMT) and amyotrophic lateral sclerosis (ALS). The management team will be available for one-on-one meetings during these conferences, emphasizing Oryzon's commitment to advancing innovation in epigenetics.
For more information, visit Oryzon's official website at www.oryzon.com. Stakeholders are encouraged to remain cautious regarding forward-looking statements, which may be subject to various risks and uncertainties that could ultimately impact business outcomes.
MWN-AI** Analysis
As Oryzon Genomics, S.A. gears up for a series of high-profile events in February and March 2026, investors should consider this an opportune moment to evaluate their position in the company. The management team's presence at influential conferences like Bio-Neuroscience 2026 and BIO-Europe Spring highlights Oryzon's commitment to showcasing its innovative pipeline and engaging with key stakeholders in the biopharmaceutical landscape.
Oryzon's focus on epigenetics, particularly its lead programs targeting central nervous system disorders and oncology, positions it favorably within a competitive market. The promising preliminary data for its LSD1 inhibitors, with vafidemstat advancing towards Phase III trials, and iadademstat showing robust early results in acute myeloid leukemia, could stimulate investor interest and optimism. Additionally, the upcoming discussions and one-on-one meetings could provide critical insights into the company’s strategic direction.
Investors should also be aware of the potential risks associated with high expectations surrounding clinical trials and regulatory approvals. The biopharmaceutical industry is notably volatile, with each operational update capable of significantly impacting stock performance.
Therefore, a prudent approach would be to monitor market reactions to these events, particularly focusing on any new data shared during presentations. Engaging in one-on-one meetings could also yield valuable insights from company executives, potentially aiding investment decisions.
As the company navigates these important events, investors may contemplate taking strategic positions, balancing the inherent risks with the potential upside from Oryzon’s advancements in epigenetic therapies. Key factors to watch will include investor sentiment post-event, competitor developments, and broader market trends affecting the biotech sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MADRID and CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events:
Bio-Neuroscience 2026, February 24-27
Location: Hotel Jakarta, Amsterdam
SmallCap Event 20th Edition, March 17
Location: Les Salons Hoche, Paris
BIO-Europe Spring 2026, March 23-25
Location: Feira Internacional de Lisboa (FIL), Lisbon
LSX World Congress Europe, March 25-26
Location: Lisbon Congress Centre, Lisbon
Presentation type: Panel Discussion
Presentation date and time: March 25, 14:00 GMT
Oryzon management will be available for one-on-one meetings during the conferences.
About Oryzon
Founded in 2000 and headquartered in Barcelona, Spain, Oryzon (ISIN: ES0167733015) is a clinical-stage biopharmaceutical company and a European leader in epigenetics, with a strong focus on personalized medicine for central nervous system (CNS) disorders and oncology. Oryzon’s team comprises highly experienced pharmaceutical professionals based in Barcelona, Boston, and New Jersey. The Company has an advanced clinical portfolio built around two LSD1 inhibitors: vafidemstat, its lead CNS program, which is Phase III–ready; and iadademstat, its oncology/hematology program, with several ongoing Phase I and II studies and outstanding preliminary results in first-line acute myeloid leukemia, including a 100% overall response rate (ORR) presented at ASH 2025. In addition, Oryzon is advancing a broader epigenetics pipeline targeting other mechanisms, including HDAC6, for which a clinical candidate, ORY-4001, has been nominated for potential development in Charcot–Marie–Tooth disease (CMT) and amyotrophic lateral sclerosis (ALS). The Company also operates a robust platform for biomarker identification and target validation across a range of malignant and neurological diseases. For more information, visit www.oryzon.com
FORWARD-LOOKING STATEMENTS
This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates” and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees, or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward?looking statements, whether as a result of new information, future events, or otherwise. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, and/or the restated text of the Securities Market Law, approved by Law 6/2023 of 17 March, and its implementing regulations. Nothing in this document constitutes investment advice. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any jurisdiction. The shares of Oryzon Genomics, S.A. may not be offered or sold in the United States of America except pursuant to an effective registration statement under the Securities Act of 1933 or pursuant to a valid exemption from registration.
| Spain | Oryzon | IR & Media, Europe & US | |
| Patricia Cobo/Mario Cordera | Emili Torrell | Sandya von der Weid | |
| Atrevia | Chief BD Officer | LifeSci Advisors, LLC | |
| +34 91 564 07 25 +34 673 33 97 65 | +34 93 515 1313 | +41 78 680 05 38 | |
| pcobo@atrevia.com mcordera@atrevia.com | etorrell@oryzon.com | svonderweid@lifesciadvisors.com |
FAQ**
How does Oryzon Genomics S.A. (ORYZF) plan to leverage its presence at events in Amsterdam and Lisbon to enhance its investor relations and market visibility?
What specific advancements in personalized medicine has Oryzon Genomics S.A. (ORYZF) achieved in its CNS and oncology programs leading into the 20conference presentations?
In what ways can the clinical results of Oryzon's lead CNS program, vafidemstat, influence investor interest in Oryzon Genomics S.A. (ORYZF) during the upcoming conferences?
How does Oryzon Genomics S.A. (ORYZF) intend to communicate its epigenetics pipeline developments to potential investors and partners at the Bio-Neuroscience 2026 event?
**MWN-AI FAQ is based on asking OpenAI questions about Oryzon Genomics S.A. (OTC: ORYZF).
NASDAQ: ORYZF
ORYZF Trading
0.0% G/L:
$3.25 Last:
3,000 Volume:
$3.25 Open:
